Double-digit growth in profits for the 18th consecutive year - dividend increase to CHF 14 per registered share proposed
Galenica increased consolidated net sales by 2.0% to CHF 3,359.4 million in 2013. On a comparable basis, profit before d…
Galenica increased consolidated net sales by 2.0% to CHF 3,359.4 million in 2013. On a comparable basis, profit before d…
The Galenica Group increased consolidated net sales by 2.0% to CHF 3,359.4 million in 2013, in a market environment char…
Velphoro® (sucroferric oxyhydroxide) has received US Food and Drug Administration (FDA) approval for the control of seru…
The Galenica Group performed well in a complex market environment during the first six months of 2013. Net sales increas…
Injectafer® has received US Food and Drug Administration (FDA) approval for the treatment of Iron Deficiency Anaemia (ID…
The Galenica Group has acquired a 49% stake in the Bahnhof Apotheke Zurich, thereby expanding its network with a highly…
Through its pharmaceutical wholesaler Galexis, Galenica is acquiring Medifilm Ltd., a leading company in the field of bl…
At the 85th Annual General Meeting of Galenica Ltd., the shareholders approved all the propos-als submitted by the Board…
Following the submission of the New Drug Application (NDA) for PA21, the US Food and Drug Administration (FDA) has annou…
Karin Priarollo is leaving Galenica by mutual agreement. She has resigned with immediate effect from her role as Head of…